[1] Freddie B M, Jacques F M, Isabelle S I,et al.Global cancer statistic 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018 (68):394-424.

[2] 陈万青,郑荣寿,张思维,等.2012年中国恶性肿瘤发病和死亡分析[J].中国肿瘤,2016 (5):1-8.

[3] 李琎, 吴小华. 宫颈癌保留生育功能的腹式根治性宫颈切除术——一项潜在获益人群的研究[J]. 中国癌症杂志, 2012, 22(6):407-412.

[4] NCCN clinical practice guidelines in Oncology:cervical cancer(2017.V1).

[5] Jemal A, Bray F, Center M M, et al. Global cancer statistics[J]. CA Cancer J Clin,2011 (61):69-90.

[6] Patel S, Liyanage S H, Sahdev A, et al. Imaging of endometrial and cervical cancer[J].Insights Imaging, 2010, 1:309-328.

[7] Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix[J]. Int J Gynaecol Obstet, 2009 (105):107-108.

[8] Downey K, Jafar M, Attygalle A D, et al. Influencing surgical management in patients with carcinoma of the cervix using a T2- and ZOOM-diffusion-weighted endovaginal MRI technique[J]. Br J Cancer, 2013 (109): 615-622.

[9] Lakhman Y, Akin O, Park K J, et al. Stage IB1 cervical cancer: role of preoperative MR imaging in selection of patients for fertility-sparing radical trachelectomy[J].Radiology, 2013 (269):149-158.

[10]殷蔚伯，余子豪，徐国镇，等.肿瘤放射治疗学[M].北京：中国协和医科大学出版社，2018，316-318.

[11] Woo S, Kim H S, Chung H H, et al. Early stage cervical cancer: role of magnetic resonance imaging after conization in determining residual tumor[J]. Acta Radiol,2016 (57):1268-1276.

[12] Kato T, Takashima A, Kasamatsu T, et al. Clinical tumor diameter and prognosis of patients with FIGO stage IB1 cervical cancer(JCOG0806-A)[J]. Gynecol Oncol,2015 (137):34-39.

[13] Cormier B, Diaz J P, Shih K, et al. Establishing a sentinel lymph node mapping algorithm for the treatment of early cervical cancer[J]. Gynecol Oncol, 2011(122):275-280.

[14] Wu Y, Li Z, Wu H, et al. Sentinel lymph node biopsy in cervical cancer: A metaanalysis[J]. Mol Clin Oncol, 2013 (1):1025-1030.

[15] Taylor A, Rockall A G, Reznek R H, et al.Mapping pelvic lymph nodes: guidelines for delineation in intensity-modulated radiotherapy[J]. Int J Radiat Oncol Biol Phys, 2005,63(5):1604-1612.

[16] Lim K, W Small, Jr., Portelance L, et al.Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer[J]. Int J Radiat Oncol Biol Phys, 2011,79(2):348-355.

[17] Haie-Meder C, Potter R, Van Limbergen E, et al.Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV[J]. Radiother Oncol, 2005, 74(3):235-245.

[18] 龙行涛，周琦.局部晚期宫颈癌治疗现状与进展[J].中国实用妇科与产科杂志,2017,11(33):1206-1209.

[19] Dimopoulos J C, Petrow P, Tanderup K, et al.Recommendations from Gynaecological(GYN) GEC-ESTRO Working Group (IV): Basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy[J].Radiother Oncol, 2012, 103(1):113-122.

[20] Wo J Y, Viswanathan A N. Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients[J]. Int J Radiat Oncol Biol Phys, 2009(73): 1304-1312.

[21] Kadkhodayan S, Hasanzadeh M, Treglia G, et al. Sentinel node biopsy for lymph nodal staging of uterine cervix cancer: a systematic review and meta-analysis of the pertinent literature[J]. Eur J Surg Oncol, 2015 (41):1-20.

[22] Mendivil A A, Rettenmaier M A, Abaid LN, et al. Survival rate comparisons amongst cervical cancer patients treated with an open, robotic-assisted or laparoscopic radical hysterectomy: A five year experience[J]. Surg Oncol, 2016 (25):66-71.

[23] Bats A S, Frati A, Mathevet P, et al. Contribution of lymphoscintigraphy to intraoperative sentinel lymph node detection in early cervical cancer: Analysis of the prospective multicenter SENTICOL cohort[J]. Gynecol Oncol, 2015 (137):264-269. [24] Peters W A, Liu P Y, Barrett R J, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix[J]. J Clin Oncol,2000 (18):1606-1613.

[25] Monk B J, Wang J, Im S, et al. Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial[J]. Gynecol Oncol, 2005 (96):721-728.

[26] Yoneda J Y, Braganca J F, Sarian L O, et al. Surgical treatment of microinvasive cervical cancer: analysis of pathologic features with implications on radicality[J].Int J Gynecol Cancer, 2015 (25):694-698.

[27] Wolfson A H, Varia M A, Moore D, et al. ACR Appropriateness Criteria(R) role of adjuvant therapy in the management of early stage cervical cancer[J]. Gynecol Oncol, 2012 (125):256-262.

[28] Atri M, Zhang Z, Dehdashti F, et al. Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer:Results of ACRIN6671/GOG0233 trial[J]. Gynecol Oncol, 2016 (142):413-419.

[29] Kokka F, Bryant A, Brockbank E, et al. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer[J].Cochrane Database Syst Rev, 2015 (4):CD010260.

[30] Tewari K S, Sill M W, Long H J, et al. Improved survival with bevacizumab in advanced cervical cancer[J]. N Engl J Med, 2014 (370):734-743.

[31] Balleyguier C, Fournet C, Ben H W, et al. Management of cervical cancer detected during pregnancy: role of magnetic resonance imaging[J]. Clin Imaging, 2013(37):70-76.

[32] Amant F, Halaska M J, Fumagalli M, et al. Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting[J]. INT J GYNECOL CANCER, 2014 (24):394-403. 7vu7H/GBohF6jW6TdDxHZlSUd0dwBdiYIXoJYXpeeHQyg+wSlvoT109CXIwM6fPK